Proangiogenic compositions and methods of use
AssigneeUniversity of North Dakota
InventorMikhail Y. Golovko
Life of this patent
Estimating the term…
Abstract
Various embodiments disclosed relate to a pharmaceutical composition. The composition includes the structure according to Formula I or pharmaceutically acceptable ester thereof, prodrug thereof, or a pharmaceutically acceptable salt thereof: In Formula I, R1, R2, R3, R4, R5, and R6, are independently selected from the group consisting of —H, —OH, —COOH, and substituted or unsubstituted (C1-C20)hydrocarbyl.
Claims20
A pharmaceutical composition, the composition comprising the structure according to Formula I or pharmaceutically acceptable ester thereof, prodrug thereof, or a pharmaceutically acceptable salt thereof:
- wherein R1, R2, R3, R4, R5, and R6, are independently selected from the group consisting of —H, —OH, —COOH, and substituted or unsubstituted (C1-C20)hydrocarbyl.
A pharmaceutical composition for promoting angiogenesis, the composition comprising the structure according to Formula I or pharmaceutically acceptable ester thereof, prodrug thereof, or a pharmaceutically acceptable salt thereof:
- wherein R1, R2, R3, R4, R5, and R6, are independently selected from the group consisting of —H, —OH, —COOH, and substituted or unsubstituted (C1-C20)hydrocarbyl.
A method for promoting angiogenesis in a subject, the method administering a composition comprising the structure according to Formula I or pharmaceutically acceptable ester thereof, prodrug thereof, or a pharmaceutically acceptable salt thereof:
- wherein R1, R2, R3, R4, R5, and R6, are independently selected from the group consisting of —H, —OH, —COOH, and substituted or unsubstituted (C1-C20)hydrocarbyl, wherein angiogenesis is generated to treat stroke, neurodegeneration, metabolic brain disorders, muscular dystrophy, or a combination thereof.
Dependencies are inferred from the claim text.